Pub Date : 2025-11-26eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2594336
Julie Hansen Niklassen, Christian Lodberg Hvas, Kristian Schønning, Kasper Sommerlund Moestrup, Marie Helleberg, Michael Perch, Elisabeth Bendstrup
Background: Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract. In transplant recipients presenting with diarrhea, alternative etiologies such as inflammatory bowel disease (IBD) should be considered. The emergence of antiviral resistance poses a therapeutic challenge, and molecular testing for resistance-associated mutations is essential in cases of treatment failure.
Case presentation: A lung transplant recipient developed chronic diarrhea leading to functional intestinal failure. CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted. Small bowel enteroscopy with biopsies showed ongoing mucosal inflammation and minimal residual CMV activity. These findings were consistent with ganciclovir-resistant CMV enteritis coexisting with de novo Crohn's disease. The patient was commenced on standard biological therapy for Crohn's disease, resulting in marked clinical improvement and recovery.
Conclusion: This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn's disease and determining the primary driver of the clinical presentation.
{"title":"Cytomegalovirus and Crohn's disease as competing causes of small bowel inflammation after double-lung transplantation.","authors":"Julie Hansen Niklassen, Christian Lodberg Hvas, Kristian Schønning, Kasper Sommerlund Moestrup, Marie Helleberg, Michael Perch, Elisabeth Bendstrup","doi":"10.1080/20018525.2025.2594336","DOIUrl":"10.1080/20018525.2025.2594336","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract. In transplant recipients presenting with diarrhea, alternative etiologies such as inflammatory bowel disease (IBD) should be considered. The emergence of antiviral resistance poses a therapeutic challenge, and molecular testing for resistance-associated mutations is essential in cases of treatment failure.</p><p><strong>Case presentation: </strong>A lung transplant recipient developed chronic diarrhea leading to functional intestinal failure. CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted. Small bowel enteroscopy with biopsies showed ongoing mucosal inflammation and minimal residual CMV activity. These findings were consistent with ganciclovir-resistant CMV enteritis coexisting with de novo Crohn's disease. The patient was commenced on standard biological therapy for Crohn's disease, resulting in marked clinical improvement and recovery.</p><p><strong>Conclusion: </strong>This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn's disease and determining the primary driver of the clinical presentation.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2594336"},"PeriodicalIF":1.4,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12667282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145660762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-21eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2591512
Mojtaba Saei, Ingeborg Farver-Vestergaard, Mads Holm Hansen, Peter Hjorth, Charlotta Pisinger, Anders Løkke
Introduction: Successful smoking cessation remains a challenge. The 'Very Brief Advice' (VBA) method is the recommended clinical practice in Denmark for referral to smoking cessation programs. This study examines how healthcare providers use the Very Brief Advice (VBA) method for smoking cessation, comparing trained and untrained staff and exploring overall referral activity at a large Danish Hospital.
Methods: A cross-sectional survey was conducted at a major hospital in the Region of Southern Denmark. HCPs reported sociodemographic and work-related information as well as their use of the VBA in daily practice. Practices of smoking cessation support beyond the VBA-method and hospital-level data on monthly referrals (May 2018 to May 2022) were assessed as a secondary objective.
Results: Between June and September 2021, a total of 1,572 (out of 3,998) HCPs with regular patient contact completed survey and were included in the study. Results show that mandatory VBA training was only undertaken by 35.6% of the participants and nearly half (46.6%) of all participants reported that they never/almost never used VBA in their daily practice. A larger proportion of nurses completed the training, compared to other HCPs. A larger proportion of outpatient staff completed the training, compared to staff in inpatient units. Referral data showed a decline in monthly VBA-referrals, dropping from 299 per months in 2018 to 96 in 2022.
Conclusion: The use of the mandatory VBA method in a larger Danish hospital is limited and declining. We observed low participation in VBA training and low utilization among HCPs. Significant adjustments and reassessment of the implementation effort are necessary.Trial registration: Not relevant.
{"title":"Using the 'very brief advice'-method for referral to smoking cessation programs.","authors":"Mojtaba Saei, Ingeborg Farver-Vestergaard, Mads Holm Hansen, Peter Hjorth, Charlotta Pisinger, Anders Løkke","doi":"10.1080/20018525.2025.2591512","DOIUrl":"10.1080/20018525.2025.2591512","url":null,"abstract":"<p><strong>Introduction: </strong>Successful smoking cessation remains a challenge. The 'Very Brief Advice' (VBA) method is the recommended clinical practice in Denmark for referral to smoking cessation programs. This study examines how healthcare providers use the Very Brief Advice (VBA) method for smoking cessation, comparing trained and untrained staff and exploring overall referral activity at a large Danish Hospital.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted at a major hospital in the Region of Southern Denmark. HCPs reported sociodemographic and work-related information as well as their use of the VBA in daily practice. Practices of smoking cessation support beyond the VBA-method and hospital-level data on monthly referrals (May 2018 to May 2022) were assessed as a secondary objective.</p><p><strong>Results: </strong>Between June and September 2021, a total of 1,572 (out of 3,998) HCPs with regular patient contact completed survey and were included in the study. Results show that mandatory VBA training was only undertaken by 35.6% of the participants and nearly half (46.6%) of all participants reported that they never/almost never used VBA in their daily practice. A larger proportion of nurses completed the training, compared to other HCPs. A larger proportion of outpatient staff completed the training, compared to staff in inpatient units. Referral data showed a decline in monthly VBA-referrals, dropping from 299 per months in 2018 to 96 in 2022.</p><p><strong>Conclusion: </strong>The use of the mandatory VBA method in a larger Danish hospital is limited and declining. We observed low participation in VBA training and low utilization among HCPs. Significant adjustments and reassessment of the implementation effort are necessary.<b>Trial registration</b>: Not relevant.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2591512"},"PeriodicalIF":1.4,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12642889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-07eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2573588
Christian Kildegaard, Amanda D Juul, Ibrahim M Slaiman, Christian B Laursen, Arman Arshad, Vasiliki Panou
Introduction: Haemoptysis, a common symptom with a variety of aetiologies, requires a comprehensive diagnostic approach. Computed tomography of the thorax (CT) and bronchoscopy are crucial in this process. This study assesses the value of bronchoscopy in patients with haemoptysis and CT with no findings suspicious of malignancy.
Methods and materials: This study retrospectively assessed patients with haemoptysis referred between January 2019 and December 2022 to the Department of Respiratory Medicine, Odense University Hospital. All patients who underwent CT and subsequently bronchoscopy due to haemoptysis were included in the study. Patients were excluded if CT or bronchoscopy was not performed, as well as patients suspected of malignancy on CT. Data, including patient characteristics, medical history, haemoptysis progression, CT, bronchoscopy results, and clinical assessments, were collected with a six-month follow-up.
Results: A total of 469 patients were assessed for eligibility, of whom 306 were excluded, resulting in 163 eligible patients. There were 95 males (58.28%), and the mean age was 57.8 years (SD 14.48). Mild haemoptysis (92.02%) and longer than one week (63.80%) was the most common presentation. CT revealed abnormal findings in 77 (47.24%) patients and for 117 (71.78%) patients followed a bronchoscopy with no abnormal observations. No malignant findings were detected by bronchoscopy.
Conclusion: The findings of this study revealed that bronchoscopy did not identify malignant aetiology beyond the scope of CT. These findings combined with current evidence suggest minimal benefit of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients. Take Home Message The diagnostic approach for patients with haemoptysis typically includes computed tomography (CT) and bronchoscopy to exclude pulmonary malignancy. This study supports current evidence of minimal value of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients.
{"title":"Value of bronchoscopy after computed tomography in the diagnostic work-up of haemoptysis.","authors":"Christian Kildegaard, Amanda D Juul, Ibrahim M Slaiman, Christian B Laursen, Arman Arshad, Vasiliki Panou","doi":"10.1080/20018525.2025.2573588","DOIUrl":"10.1080/20018525.2025.2573588","url":null,"abstract":"<p><strong>Introduction: </strong>Haemoptysis, a common symptom with a variety of aetiologies, requires a comprehensive diagnostic approach. Computed tomography of the thorax (CT) and bronchoscopy are crucial in this process. This study assesses the value of bronchoscopy in patients with haemoptysis and CT with no findings suspicious of malignancy.</p><p><strong>Methods and materials: </strong>This study retrospectively assessed patients with haemoptysis referred between January 2019 and December 2022 to the Department of Respiratory Medicine, Odense University Hospital. All patients who underwent CT and subsequently bronchoscopy due to haemoptysis were included in the study. Patients were excluded if CT or bronchoscopy was not performed, as well as patients suspected of malignancy on CT. Data, including patient characteristics, medical history, haemoptysis progression, CT, bronchoscopy results, and clinical assessments, were collected with a six-month follow-up.</p><p><strong>Results: </strong>A total of 469 patients were assessed for eligibility, of whom 306 were excluded, resulting in 163 eligible patients. There were 95 males (58.28%), and the mean age was 57.8 years (SD 14.48). Mild haemoptysis (92.02%) and longer than one week (63.80%) was the most common presentation. CT revealed abnormal findings in 77 (47.24%) patients and for 117 (71.78%) patients followed a bronchoscopy with no abnormal observations. No malignant findings were detected by bronchoscopy.</p><p><strong>Conclusion: </strong>The findings of this study revealed that bronchoscopy did not identify malignant aetiology beyond the scope of CT. These findings combined with current evidence suggest minimal benefit of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients. Take Home Message The diagnostic approach for patients with haemoptysis typically includes computed tomography (CT) and bronchoscopy to exclude pulmonary malignancy. This study supports current evidence of minimal value of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2573588"},"PeriodicalIF":1.4,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12599340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Asthma is a chronic respiratory condition characterized by airway inflammation and hyperreactivity. Previous studies have suggested a potential association between asthma and bacterial colonization of the upper respiratory tract. This systematic review and meta-analysis aimed to compare bacterial carriage rates, specifically focusing on Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus, among individuals with and without asthma.
Methods: We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) in reporting this meta-analysis.
Results: A total of 619 records were initially identified, leading to the inclusion of eight studies that met predefined inclusion criteria. The pooled prevalence rates of bacterial carriage were analyzed using a fixed-effect model. The risk of bias assessment was conducted using the Newcastle-Ottawa Scale. A total of 5,399 subjects were included, comprising 1,572 (29.11%) individuals with asthma and 3,827 (70.88%) without asthma. The prevalence of S. pneumoniae carriage was significantly higher in individuals with asthma (30.8%, 95% CI: 19.5-42.1%) compared to those without (19.2%, 95% CI: 8.3-30%) with an odds ratio (OR) of 1.35 (95% CI: 1.10-1.66, p = 0.005; I2 = 29%). In contrast, H. influenzae carriage rates were similar between groups (18.6% in individuals with asthma vs. 21.4% with no asthma; OR = 0.93, p = 0.84; I2 = 0%). The prevalence of M. catarrhalis was low in individuals with asthma (4.7%), and the data for S. aureus was limited, showing a prevalence of 36.67% among individuals with asthma compared to 26.67% with no asthma.
Conclusion: This systematic review and meta-analysis showed that asthma may increase the risk of S. pneumoniae carriage. The similar carriage rates of H. influenzae between the two groups suggest distinct mechanisms of bacterial colonization, underscoring the need to further investigate asthma's role in predisposing individuals to specific bacterial infections.
{"title":"Asthma is associated with increased <i>Streptococcus pneumoniae</i> carriage in the upper airway: a systematic review and meta-analysis.","authors":"Raeni Dwi Putri, Chrysanti Murad, Kuswandewi Mutyara","doi":"10.1080/20018525.2025.2569129","DOIUrl":"10.1080/20018525.2025.2569129","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a chronic respiratory condition characterized by airway inflammation and hyperreactivity. Previous studies have suggested a potential association between asthma and bacterial colonization of the upper respiratory tract. This systematic review and meta-analysis aimed to compare bacterial carriage rates, specifically focusing on <i>Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis</i>, and <i>Staphylococcus aureus</i>, among individuals with and without asthma.</p><p><strong>Methods: </strong>We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) in reporting this meta-analysis.</p><p><strong>Results: </strong>A total of 619 records were initially identified, leading to the inclusion of eight studies that met predefined inclusion criteria. The pooled prevalence rates of bacterial carriage were analyzed using a fixed-effect model. The risk of bias assessment was conducted using the Newcastle-Ottawa Scale. A total of 5,399 subjects were included, comprising 1,572 (29.11%) individuals with asthma and 3,827 (70.88%) without asthma. The prevalence <i>of S. pneumoniae</i> carriage was significantly higher in individuals with asthma (30.8%, 95% CI: 19.5-42.1%) compared to those without (19.2%, 95% CI: 8.3-30%) with an odds ratio (OR) of 1.35 (95% CI: 1.10-1.66, <i>p</i> = 0.005; I<sup>2</sup> = 29%). In contrast, <i>H. influenzae</i> carriage rates were similar between groups (18.6% in individuals with asthma vs. 21.4% with no asthma; OR = 0.93, <i>p</i> = 0.84; I<sup>2</sup> = 0%). The prevalence of <i>M. catarrhalis</i> was low in individuals with asthma (4.7%), and the data for <i>S. aureus</i> was limited, showing a prevalence of 36.67% among individuals with asthma compared to 26.67% with no asthma.</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis showed that asthma may increase the risk of <i>S. pneumoniae</i> carriage. The similar carriage rates of <i>H. influenzae</i> between the two groups suggest distinct mechanisms of bacterial colonization, underscoring the need to further investigate asthma's role in predisposing individuals to specific bacterial infections.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2569129"},"PeriodicalIF":1.4,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12590569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145481098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-02eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2581331
Stefanie Eck, Andrea Baumgärtel, Alexander Hapfelmeier, Klaus Linde, Linda Sanftenberg, Stefanie Stark, Antonius Schneider
Objective: Education programs are essential to involve individuals with asthma in disease management and improve outcomes. We aimed to investigate the effects of a pilot-tested online asthma education program (eAEP) on autonomy preferences and medication behavior in adults with asthma in general practices.
Methods: We performed a pre-planned secondary analysis of a cluster randomized trial comparing the eAEP with usual care (UC) in terms of Asthma Knowledge Test (AKT) scores. The Autonomy Preference Index (API) was used to assess patients' preferences for information (information preference) and involvement in medical decisions (participation preference). Participants evaluated eight statements regarding medication behavior. Outcomes were analyzed at baseline and six months.
Results: A total of 108 asthma patients (mean age: 47 years, 59% female) were analyzed. Increases in AKT scores were substantially larger in intervention groups (7.9 (95% CI 4.9-10.8), p < 0.001). API subscale scores increased in intervention and control groups, but group-differences were not statistically significant (participation preference: 2.8 (95% CI -4.1-9.6), p = 0.421; information preference: 1.1 (95% CI -1.8-4.1), p = 0.471). There was a positive correlation between changes in AKT and participation preference (r = 0.27, p = 0.031), but not information preference scores (r = 0.08, p = 0.472). Regarding medication behavior, there were some improvements in individual items in intervention groups, but no consistent patterns indicating a clear influence of API scores.
Conclusions: The eAEP did not result in larger increases in autonomy preferences compared to UC, but indicated beneficial effects on some forms of medication behavior. Larger studies are required for further insights.
目的:教育项目对哮喘患者参与疾病管理和改善预后至关重要。我们的目的是调查一个试点测试的在线哮喘教育项目(eAEP)对普通哮喘成人患者自主偏好和用药行为的影响。方法:我们对一项分组随机试验进行了预先计划的二次分析,比较了eAEP与常规护理(UC)在哮喘知识测试(AKT)评分方面的差异。自主偏好指数(API)用于评估患者对信息的偏好(信息偏好)和参与医疗决策的偏好(参与偏好)。参与者评估了八项关于药物行为的陈述。在基线和6个月时分析结果。结果:共分析108例哮喘患者(平均年龄47岁,女性59%)。干预组AKT评分的增加幅度更大(7.9 (95% CI 4.9-10.8), p p = 0.421;信息偏好:1.1 (95% CI -1.8-4.1), p = 0.471)。AKT的变化与参与偏好呈正相关(r = 0.27, p = 0.031),与信息偏好得分呈正相关(r = 0.08, p = 0.472)。在用药行为方面,干预组在个别项目上有一定的改善,但没有一致的模式表明API评分有明显的影响。结论:与UC相比,eAEP并没有导致自主性偏好的更大增加,但对某些形式的药物行为有有益的影响。需要更大规模的研究来进一步了解。
{"title":"Autonomy preferences and behaviors towards asthma medication in online asthma education: a secondary analysis of a cluster randomized controlled trial in adults with asthma.","authors":"Stefanie Eck, Andrea Baumgärtel, Alexander Hapfelmeier, Klaus Linde, Linda Sanftenberg, Stefanie Stark, Antonius Schneider","doi":"10.1080/20018525.2025.2581331","DOIUrl":"10.1080/20018525.2025.2581331","url":null,"abstract":"<p><strong>Objective: </strong>Education programs are essential to involve individuals with asthma in disease management and improve outcomes. We aimed to investigate the effects of a pilot-tested online asthma education program (eAEP) on autonomy preferences and medication behavior in adults with asthma in general practices.</p><p><strong>Methods: </strong>We performed a pre-planned secondary analysis of a cluster randomized trial comparing the eAEP with usual care (UC) in terms of Asthma Knowledge Test (AKT) scores. The Autonomy Preference Index (API) was used to assess patients' preferences for information (information preference) and involvement in medical decisions (participation preference). Participants evaluated eight statements regarding medication behavior. Outcomes were analyzed at baseline and six months.</p><p><strong>Results: </strong>A total of 108 asthma patients (mean age: 47 years, 59% female) were analyzed. Increases in AKT scores were substantially larger in intervention groups (7.9 (95% CI 4.9-10.8), <i>p</i> < 0.001). API subscale scores increased in intervention and control groups, but group-differences were not statistically significant (participation preference: 2.8 (95% CI -4.1-9.6), <i>p</i> = 0.421; information preference: 1.1 (95% CI -1.8-4.1), <i>p</i> = 0.471). There was a positive correlation between changes in AKT and participation preference (<i>r</i> = 0.27, <i>p</i> = 0.031), but not information preference scores (<i>r</i> = 0.08, <i>p</i> = 0.472). Regarding medication behavior, there were some improvements in individual items in intervention groups, but no consistent patterns indicating a clear influence of API scores.</p><p><strong>Conclusions: </strong>The eAEP did not result in larger increases in autonomy preferences compared to UC, but indicated beneficial effects on some forms of medication behavior. Larger studies are required for further insights.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2581331"},"PeriodicalIF":1.4,"publicationDate":"2025-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12581774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2580788
Matthew Shorthose, Rebecca Crook, Rahul Bhatnagar
Background: Malignant pleural effusion (MPE) occurs in up to 20% of malignancies, most commonly from a breast or pulmonary primary. It confers a poor prognosis, with a median survival of less than a year, and the mainstay in treatment has previously been achieving pleurodesis.
Aims and methods: This review provides an overview of the most up to date literature for the treatment of MPE using a PubMed search, with a focus on patient-centred care.
Results: There is increased focus on outpatient management and control of symptoms for patients with MPE, allowing more in-depth conversations to be had over what individual patient goals are. The development of new approaches such as indwelling pleural catheters (IPC) and local anaesthetic thoracoscopy (LAT) also increase the options available. When manging the complexities of MPE, such as non-expansile lung and septated effusions, various approaches can be taken to treat them including fibrinolytics and IPC.
Discussion: The treatment of MPE has changed in the last 15 years to focus on outpatient management and symptom control. Careful discussions must be undertaken on a patient-by-patient basis.
{"title":"A patient-centred approach to malignant pleural effusion.","authors":"Matthew Shorthose, Rebecca Crook, Rahul Bhatnagar","doi":"10.1080/20018525.2025.2580788","DOIUrl":"10.1080/20018525.2025.2580788","url":null,"abstract":"<p><strong>Background: </strong>Malignant pleural effusion (MPE) occurs in up to 20% of malignancies, most commonly from a breast or pulmonary primary. It confers a poor prognosis, with a median survival of less than a year, and the mainstay in treatment has previously been achieving pleurodesis.</p><p><strong>Aims and methods: </strong>This review provides an overview of the most up to date literature for the treatment of MPE using a PubMed search, with a focus on patient-centred care.</p><p><strong>Results: </strong>There is increased focus on outpatient management and control of symptoms for patients with MPE, allowing more in-depth conversations to be had over what individual patient goals are. The development of new approaches such as indwelling pleural catheters (IPC) and local anaesthetic thoracoscopy (LAT) also increase the options available. When manging the complexities of MPE, such as non-expansile lung and septated effusions, various approaches can be taken to treat them including fibrinolytics and IPC.</p><p><strong>Discussion: </strong>The treatment of MPE has changed in the last 15 years to focus on outpatient management and symptom control. Careful discussions must be undertaken on a patient-by-patient basis.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2580788"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12581772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2580795
Vasiliki Panou, Jens Benn Sørensen, Jesper Ravn, Eric Santoni-Rugiu
Pleural mesothelioma (PM) is a rare, aggressive malignancy of the pleura. The PM diagnosis is challenging, both in terms of imaging, sampling of representative biopsies and pathological examination, and the treatment options are limited. The main aim of this article is to summarize the most recent advances in the diagnosis and management of PM as presented in the Danish clinical guidelines for PM. An expert task force consisting of a lung physician, a pathologist, an oncologist, and a thoracic surgeon conducted an ad hoc literature search during November 2023-July 2024, reviewed the evidence and developed the current clinical guidelines after reaching consensus. The article appraises the radiological modalities and biopsy techniques that are employed in PM diagnostics, provides a comprehensive overview of the evidence behind the PM histopathological and cytological diagnosis, and asserts the state of the art and novel developments of oncological, multimodal, and palliative PM treatment and follow-up that are portrayed in the Danish clinical guidelines.
{"title":"Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.","authors":"Vasiliki Panou, Jens Benn Sørensen, Jesper Ravn, Eric Santoni-Rugiu","doi":"10.1080/20018525.2025.2580795","DOIUrl":"10.1080/20018525.2025.2580795","url":null,"abstract":"<p><p>Pleural mesothelioma (PM) is a rare, aggressive malignancy of the pleura. The PM diagnosis is challenging, both in terms of imaging, sampling of representative biopsies and pathological examination, and the treatment options are limited. The main aim of this article is to summarize the most recent advances in the diagnosis and management of PM as presented in the Danish clinical guidelines for PM. An expert task force consisting of a lung physician, a pathologist, an oncologist, and a thoracic surgeon conducted an ad hoc literature search during November 2023-July 2024, reviewed the evidence and developed the current clinical guidelines after reaching consensus. The article appraises the radiological modalities and biopsy techniques that are employed in PM diagnostics, provides a comprehensive overview of the evidence behind the PM histopathological and cytological diagnosis, and asserts the state of the art and novel developments of oncological, multimodal, and palliative PM treatment and follow-up that are portrayed in the Danish clinical guidelines.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2580795"},"PeriodicalIF":1.4,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12573557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-27eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2577531
Amund Gulsvik, Per Sigvald Bakke, Knut Stavem
The first formal meeting of Nordic professors in pulmonary medicine took place in Gothenburg in December 1995. In Reykjavik in June 2003, the laws and statutes of the Nordic Respiratory Academy (NORA) were approved, and the first board was elected. NORA aimed to improve education, research, and clinical practice and became a meeting place for building friendships and exchange of ideas among academic teachers in pulmonary medicine in the Nordic region. The meetings initiated cooperative research among the university departments of respiratory medicine, and NORA reestablished the Nordic chest physicians' own pulmonary medical journal with roots in the Nordic region. Until 2025, 20 NORA meetings have been held. Its future depends on the perceived need for such a meeting place and academics that are willing to continue organizing and using this institution as a think tank.
{"title":"Nordic Respiratory Academy: a historical note and reflection.","authors":"Amund Gulsvik, Per Sigvald Bakke, Knut Stavem","doi":"10.1080/20018525.2025.2577531","DOIUrl":"10.1080/20018525.2025.2577531","url":null,"abstract":"<p><p>The first formal meeting of Nordic professors in pulmonary medicine took place in Gothenburg in December 1995. In Reykjavik in June 2003, the laws and statutes of the Nordic Respiratory Academy (NORA) were approved, and the first board was elected. NORA aimed to improve education, research, and clinical practice and became a meeting place for building friendships and exchange of ideas among academic teachers in pulmonary medicine in the Nordic region. The meetings initiated cooperative research among the university departments of respiratory medicine, and NORA reestablished the Nordic chest physicians' own pulmonary medical journal with roots in the Nordic region. Until 2025, 20 NORA meetings have been held. Its future depends on the perceived need for such a meeting place and academics that are willing to continue organizing and using this institution as a think tank.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2577531"},"PeriodicalIF":1.4,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12570218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-07eCollection Date: 2025-01-01DOI: 10.1080/20018525.2025.2569135
Alma Holm Rovsing, Richard Ssegonja, Christer Janson, Anders Løkke, Rikke Ibsen, Ole Hilberg, Vibeke Backer, Charlotte Suppli Ulrik, Ulla Møller Weinreich, Kjell Erik Julius Håkansson
Introduction: The financial burden of asthma in young adults remains sparsely investigated. Our study aims to estimate the Swedish national financial burden of asthma in adults aged 18-45 using nationwide databases.
Methods: The financial burden of asthma in Sweden was estimated using the Swedish burden of disease, cost of medical care, and sick leave utilization data from 2022, together with healthcare consumption estimates from a nationwide burden of asthma study (data from 2014 to 2018). Costs were calculated as total costs and excess costs compared to matched controls.
Results: The total annual financial burden for individuals with asthma was €3,572 per patient, divided into primary care (€929), secondary care (€1,137), medicine (€605), and sick leave transfers (€902). When compared to an age-, sex-, cohabitation-status-, and residence-matched control group, an annual excess cost of €2,299 (2,288-2,310) per patient with asthma was found. When stratified according to disease severity, patients at GINA 2020 Step 2 incurred the lowest annual cost at €2,916 (2,960-3,092), whereas GINA 2020 Step 5 represented the highest annual cost at €6,697 (6,559-6,793). Pooling the total mean costs for all young Swedish adults with ICS-treated asthma (n = 88,898) revealed an excess annual financial burden of €204,375,739, of which 39% (€ 80,150,137) were sick leave transfers.
Conclusion: Asthma in Sweden is associated with a substantial financial burden from both direct costs and asthma-related sick leave compared to matched controls, and the pooled excess burden of ICS-treated asthma in young adults exceeded €200,000,000 annually.
{"title":"Estimating the financial burden of asthma among young adults in Sweden.","authors":"Alma Holm Rovsing, Richard Ssegonja, Christer Janson, Anders Løkke, Rikke Ibsen, Ole Hilberg, Vibeke Backer, Charlotte Suppli Ulrik, Ulla Møller Weinreich, Kjell Erik Julius Håkansson","doi":"10.1080/20018525.2025.2569135","DOIUrl":"10.1080/20018525.2025.2569135","url":null,"abstract":"<p><strong>Introduction: </strong>The financial burden of asthma in young adults remains sparsely investigated. Our study aims to estimate the Swedish national financial burden of asthma in adults aged 18-45 using nationwide databases.</p><p><strong>Methods: </strong>The financial burden of asthma in Sweden was estimated using the Swedish burden of disease, cost of medical care, and sick leave utilization data from 2022, together with healthcare consumption estimates from a nationwide burden of asthma study (data from 2014 to 2018). Costs were calculated as total costs and excess costs compared to matched controls.</p><p><strong>Results: </strong>The total annual financial burden for individuals with asthma was €3,572 per patient, divided into primary care (€929), secondary care (€1,137), medicine (€605), and sick leave transfers (€902). When compared to an age-, sex-, cohabitation-status-, and residence-matched control group, an annual excess cost of €2,299 (2,288-2,310) per patient with asthma was found. When stratified according to disease severity, patients at GINA 2020 Step 2 incurred the lowest annual cost at €2,916 (2,960-3,092), whereas GINA 2020 Step 5 represented the highest annual cost at €6,697 (6,559-6,793). Pooling the total mean costs for all young Swedish adults with ICS-treated asthma (<i>n</i> = 88,898) revealed an excess annual financial burden of €204,375,739, of which 39% (€ 80,150,137) were sick leave transfers.</p><p><strong>Conclusion: </strong>Asthma in Sweden is associated with a substantial financial burden from both direct costs and asthma-related sick leave compared to matched controls, and the pooled excess burden of ICS-treated asthma in young adults exceeded €200,000,000 annually.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2569135"},"PeriodicalIF":1.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12509292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}